Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Condition: Acne Vulgaris
MeSH terms: Acne Vulgaris
Intervention: Aczone Gel
Intervention description: Aczone Gel 7.5%
Intervention MeSH terms: Dapsone
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 20.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: skin of color; acne; skin diseases

Summary:

      Acne vulgaris is a common skin disease characterized by inflammatory papules, pustules, and
      comedones that is prevalent in men and women of color. Research has demonstrated that Aczone
      ® (dapsone) gel, 7.5% used once daily is effective, safe, and well-tolerated for the
      treatment of acne in both men and women; however, limited data is available regarding its
      efficacy and safety in skin of color (SOC). The current study aims to investigate the
      therapeutic impact of Aczone gel 7.5% in SOC males and females ages 18 and older with acne
      vulgaris. The study will also evaluate the impact of Aczone ® gel on hyperpigmentation and
      PIH of the face.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Provide written, signed and dated informed consent prior to initiating any
             study-related activities.

          -  Male or female subjects who are ≥ 18 years of age

          -  Subjects with Fitzpatrick Skin Type IV, V, or VI

          -  Subjects with moderate to severe acne as defined by investigator- assessed Global Acne
             Assessment Score (GAAS) of 3 or 4 at screening

          -  Facial acne vulgaris with 20 to 50 (inclusive) inflammatory lesions and 30 to 100
             (inclusive)non inflammatory lesion

          -  Stable non-progressive or regressive acne vulgaris in the investigator's opinion

          -  Females of childbearing potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. A female is considered not to be of childbearing potential if
             she is post-menopausal with at least 12 consecutive months of amenorrhea or has
             undergone surgical sterilization. While on investigational product and for at least 28
             days after taking the last dose of investigational product, FCBP who engage in
             activity in which conception is possible must use one of the approved contraceptive
             options described below:

        Option 1: Any one of the following highly effective methods: hormonal contraception (oral,
        injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal
        ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or
        nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS
        one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with
        spermicide; or (c) contraceptive sponge with spermicide.

          -  Must be in general good as judged by the Investigator

          -  Subject is willing to avoid excessive or prolonged exposure of the treated skin to
             ultraviolet light (i.e. sunlight, tanning beds) throughout the study

          -  Subject is willing to follow study instructions and complete study assessments without
             assistance and is likely to complete all required visits

        Exclusion Criteria:

          -  Diagnosis of other dermatologic diagnosis that, in the opinion of the investigator,
             would interfere with diagnosis, examination, or treatment of the studied condition
             (i.e. psoriasis, atopic dermatitis, lupus, dermatomyositis, seborrheic dermatitis,
             perioral dermatitis, etc.)

          -  Subjects with severe cystic acne, acne conglobate, acne fulminans, or secondary acne
             (chloracne or drug-induced acne)

          -  Uncontrolled systemic disease(s) that, in the opinion of the investigator, would put
             the patient at significant risk if enrolled in the study or would interfere with
             subject's participation in the study

          -  Subjects with a history of clinically significant hemolysis, anemia, or enteritis
             (regional enteritis, ulcerative colitis, pseudomembranous colitis,
             antibiotic-associated colitis)

          -  Subjects with allergy or sensitivity to the study drug or its components

          -  Subjects who have not complied with the proper wash-out periods:

               -  Topical anti-inflammatory medications, salicylic acid, corticosteroids,
                  antibiotics, antibacterials, peroxide-containing products, or retinoids within 2
                  weeks of baseline

               -  Systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4
                  weeks of baseline Other anti-acne medication, including isotretinoin or
                  spironolactone, within 6 months of baseline

               -  Chemical peels or other facial acne procedures (laser therapy, light therapy)
                  within 3 months of baseline

               -  Treatment with botulinum toxin of any serotype in the face within 6 months of
                  baseline

               -  Estrogens/Birth control pills must have been started ≥ 90 days prior to baseline
                  and use must be continued during the study without alteration or discontinuation.

               -  Pregnant or breast feeding.

               -  Subjects with evidence of alcohol or substance abuse.

               -  Use of any investigational drug within 4 weeks prior to randomization, or 5
                  pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).